Drug development trials aimed to halt Alzheimer’s disease (AD) progression favour recruitment of participants at early stages, preferably before symptomatic onset. In this investigation, we developed a deep-learning framework to differentiate participants with accelerated cognitive decline from those that remain cognitively stable within 24 months.